Krause Mechthild, Alsner Jan, Linge Annett, Bütof Rebecca, Löck Steffen, Bristow Rob
German Cancer Consortium (DKTK), Partner Site Dresden, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Mol Oncol. 2020 Jul;14(7):1569-1576. doi: 10.1002/1878-0261.12671. Epub 2020 Apr 8.
Radiotherapy has been optimized over the last decades not only through technological advances, but also through the translation of biological knowledge into clinical treatment schedules. Optimization of fractionation schedules and/or the introduction of simultaneous combined systemic treatment have significantly improved tumour cure rates in several cancer types. With modern techniques, we are currently able to measure factors of radiation resistance or radiation sensitivity in patient tumours; the definition of new biomarkers is expected to further enable personalized treatments. In this Review article, we overview important translation paths and summarize the quality requirements for preclinical and translational studies that will help to avoid bias in trial results.
在过去几十年里，放射治疗不仅通过技术进步得到了优化，还通过将生物学知识转化为临床治疗方案得以优化。分割方案的优化和/或同步联合全身治疗的引入显著提高了几种癌症类型的肿瘤治愈率。借助现代技术，我们目前能够测量患者肿瘤中的放射抗性或放射敏感性因素；预计新生物标志物的定义将进一步推动个性化治疗。在这篇综述文章中，我们概述了重要的转化路径，并总结了临床前和转化研究的质量要求，这些要求将有助于避免试验结果出现偏差。
